Literature DB >> 7579052

Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group.

S Klahr1, J A Breyer, G J Beck, V W Dennis, J A Hartman, D Roth, T I Steinman, S R Wang, M E Yamamoto.   

Abstract

In the Modification of Diet in Renal Disease Study, a follow-up (mean, 2.2 yr) of 200 study participants with autosomal dominant polycystic kidney disease (ADPKD) was conducted to determine the effect of lowering protein intake and blood pressure on the rate of decline in GFR. The rate of decline was faster in participants with ADPKD than in persons with other diagnoses, reflecting, in part, faster disease progression in the ADPKD group. Baseline characteristics that predicted a faster rate of decline in GFR in persons with ADPKD were greater serum creatinine (independent of GFR), greater urinary protein excretion, higher mean arterial pressure (MAP), and younger age. In patients with initial GFR values between 25 and 55 mL/min per 1.73 m2, neither assignment to a low-protein diet group nor assignment to a low blood pressure group significantly reduced the rate of decline of GFR in ADPKD participants. Similarly, the decline in GFR was not related to achieved protein intake or MAP. In participants with GFR values between 13 and 24 mL/min per 1.73 m2, assignment to the low MAP group led to a somewhat more rapid decline in GFR. However, the more rapid decline in GFR did not appear to be due to a detrimental effect of low blood pressure or the antihypertensive agents used to reach the low blood pressure goal. Lower protein intake, but not prescription of the keto acid-amino acid supplement, was marginally associated with a slower progression of renal disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579052     DOI: 10.1681/ASN.V5122037

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  64 in total

Review 1.  Recent advances: nephrology.

Authors:  C R Tomson
Journal:  BMJ       Date:  2000-01-08

2.  Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Kaleab Z Abebe; Arlene B Chapman; Robert W Schrier; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Charity G Moore; Ronald D Perrone
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

3.  Blood pressure in early autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kaleab Z Abebe; Ronald D Perrone; Vicente E Torres; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Kyongtae T Bae; Charity G Moore; Arlene B Chapman
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

4.  Geographic differences in the increasing ESRD rate have disappeared in Japan.

Authors:  Tamaki Wakamatsu-Yamanaka; Michio Fukuda; Ryo Sato; Takehiro Naito; Hiroyuki Togawa; Tatsuya Tomonari; Yoko Kato; Toshiyuki Miura; Masashi Mizuno; Tadashi Ichikawa; Sota Miyagi; Yuichi Shirasawa; Akinori Ito; Atsuhiro Yoshida; Genjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2011-06-03       Impact factor: 2.801

5.  Oral supplement of six selective amino acids arrest progression renal failure in uremic patients.

Authors:  Hippocrates Yatzidis
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 6.  Negative trials in nephrology: what can we learn?

Authors:  James E Novak; Jula K Inrig; Uptal D Patel; Robert M Califf; Lynda A Szczech
Journal:  Kidney Int       Date:  2008-06-18       Impact factor: 10.612

7.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

8.  Polycystic kidney disease: Progression of polycystic kidney disease--a lack of progress?

Authors:  Stephen McDonald; Gopala Rangan
Journal:  Nat Rev Nephrol       Date:  2014-08-05       Impact factor: 28.314

9.  A young patient with a family history of hypertension.

Authors:  Aldo J Peixoto
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-04       Impact factor: 8.237

10.  Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease.

Authors:  Ladan Zand; Vicente E Torres; Timothy S Larson; Bernard F King; Sanjeev Sethi; Eric J Bergstralh; Andrea Angioi; Fernando C Fervenza
Journal:  Nephrol Dial Transplant       Date:  2015-11-27       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.